Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies
Journal Title: Turkish Journal of Hematology - Year 2018, Vol 35, Issue 1
Abstract
Invasive fungal infections caused by drug-resistant organisms are an emerging threat to heavily immunosuppressed patients with hematological malignancies. Modern early antifungal treatment strategies, such as prophylaxis and empirical and preemptive therapy, result in long-term exposure to antifungal agents, which is a major driving force for the development of resistance. The extended use of central venous catheters, the nonlinear pharmacokinetics of certain antifungal agents, neutropenia, other forms of intense immunosuppression, and drug toxicities are other contributing factors. The widespread use of agricultural and industrial fungicides with similar chemical structures and mechanisms of action has resulted in the development of environmental reservoirs for some drug-resistant fungi, especially azole-resistant Aspergillus species, which have been reported from four continents. The majority of resistant strains have the mutation TR34/L98H, a finding suggesting that the source of resistance is the environment. The global emergence of new fungal pathogens with inherent resistance, such as Candida auris, is a new public health threat. The most common mechanism of antifungal drug resistance is the induction of efflux pumps, which decrease intracellular drug concentrations. Overexpression, depletion, and alteration of the drug target are other mechanisms of resistance. Mutations in the ERG11 gene alter the protein structure of C-demethylase, reducing the efficacy of antifungal triazoles. Candida species become echinocandin-resistant by mutations in FKS genes. A shift in the epidemiology of Candida towards resistant non-albicans Candida spp. has emerged among patients with hematological malignancies. There is no definite association between antifungal resistance, as defined by elevated minimum inhibitory concentrations, and clinical outcomes in this population. Detection of genes or mutations conferring resistance with the use of molecular methods may offer better predictive values in certain cases. Treatment options for resistant fungal infections are limited and new drugs with novel mechanisms of actions are needed. Prevention of resistance through antifungal stewardship programs is of paramount importance.
Authors and Affiliations
Maria N. Gamaletsou, Thomas J. Walsh, Nikolaos V. Sipsas
Keywords
Related Articles
- EP ID EP268105
- DOI 10.4274/tjh.2018.0007
- Views 94
- Downloads 0
Intraleukocytic Candida is diagnostic of pathological candidemia
Candidemia is the presence of Candida species in blood. It is the most frequently encountered invasive fungal infection (IFI) in hospitalized patients, and ranks as the fourth most common cause of nosocomial blood stream...
Gaucher Hücreleri ya da Pseudo-Gaucher Hücreleri: İşte Soru Bu
Auer Rod-Like Inclusions in Reactive Plasma Cells in a Case of Acute Myeloid Leukemia
.
Karbamazepin ve Hematolojik Maligniteler
Extramedullary Plasmacytoma Presenting as a Mediastinal Mass: A Comment
To the Editor, We read with great interest the recent publication about extramedullary plasmacytoma (EMP) by Shukla et al., in which they concluded that plasmacytoma involving the mediastinum is an early indication of t...